Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 268-273

  Hata, Akito ^a   Katakami, Nobuyuki ^a   Yoshioka, Hiroshige ^c   Fujita, Shiro ^a   Kunimasa, Kei ^c   Nanjo, Shigeki ^a   Otsuka, Kyoko ^a   Kaji, Reiko ^a   Tomii, Keisuke ^b   Iwasaku, Masahiro ^c   Nishiyama, Akihiro ^c   Hayashi, Hidetoshi ^c   Morita, Satoshi ^d   Ishida, Tadashi ^c  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Erlotinib; Failure; Gefitinib; Non small cell lung cancer; Performance status; Response

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; VINORELBINE DITARTRATE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-1; HUMANS; INSURANCE BENEFITS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 80053626649     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.010     Document Type: Article

References (25)

1. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small-cell lung cancer: results from a randomised, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer). Lancet 2005, 366:1527-1537.
2. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
3. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
4. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
5. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007, 25:2528-2533.
6. Lee D.H., Kim S.W., Suh C., Yoon D.H., Yi E.J., Lee J.S. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008, 19:2039-2042.
7. Zhou Z.T., Xu X.H., Wei Q., Lu M.Q., Wang J., Wen C.H. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol 2009, 64:1123-1127.
8. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-221.
9. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
10. Kaira K., Naito T., Takahashi T., Ayabe E., Shimoyama R., Kaira R., et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010, 68:99-104.
11. Vasile E., Tibaldi C., Falcone A. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?. Ann Oncol 2009, 20:790-791.
12. Hotta K., Kiura K., Takigawa N., Suzuki E., Yoshioka H., Okada T., et al. Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer 2010, (April) [Epub ahead of print].
13. Hesketh P.J., Chansky K., Wozniak A.J., Hirsch F.R., Spreafico A., Moon J., et al. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 2008, 3:1026-1031.
14. Omuro A.M., Kris M.G., Miller V.A., Franceschi E., Shah N., Milton D.T., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103:2344-2348.
15. Lee Y.J., Choi H.J., Kim S.K., Chang J., Moon J.W., Park I.K., et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010, 116:1336-1343.
16. Katayama T., Shimizu J., Suda K., Onozato R., Fukui T., Ito S., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009, 4:1415-1419.
17. Tomizawa Y., Fujita Y., Tamura A., Shirai M., Shibata S., Kawabata T., et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 2010, 68:269-272.
18. Yokouchi H., Yamazaki K., Kinoshita I., Konishi J., Asahina H., Sukoh N., et al. Clinical benefit of readministration of gefitinib for initial gefitinib responders with non-small cell lung cancer. BMC Cancer 2007, 7:51.
19. Costa D.B., Schumer S.T., Tenen D.G., Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008, 26:1182-1184.
20. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
21. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
22. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
23. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
24. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
25. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Jänne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.